Table 2.

Group Comparison of change in Observer Ratings of Irritability from Baseline to Days 28 and 60 for Intention-To-Treat Analyses of Amantadine (n=82) Versus Placebo Groups (n=86)

Variable	Group	Mean	Median	SD	p value	Adjusted p value threshold	% improved by >2 points	% difference (95% CI)	p value	Adjusted p value threshold
Baseline to day 28
NPI-I Most Problematic	Placebo	−3.58	−4.00	3.36	0.9606	0.05	66.7%	−.4% (−14.7% to +13.9%)	0.9554	0.025
	Amantadine	−3.69	−4.00	3.39			66.3%
NPI-I Distress	Placebo	−1.03	−1.00	1.32	0.1184	0.05
	Amantadine	−1.38	−1.00	1.44
NPI-I Most Aberrant post hoc	Placebo	−3.68	−4.00	3.27	0.9443	0.025	70.4%	−10.4% (−24.7% to +3.9%)		0.05
	Amantadine	−3.74	−3.50	3.56			60.0%		0.1672
Baseline to day 60
NPI-I Most Problematic	Placebo	−3.80	−4.00	3.42	0.1203	0.025	68.3%	+6.4% (−7.2% to+20%)	0.3777	0.05
	Amantadine	−4.68	−5.00	3.12			74.7%
NPI-I Distress	Placebo	−1.33	−1.00	1.39	0.1139	0.017
	Amantadine	−1.62	−2.00	1.29
NPI-I Most Aberrant post hoc	Placebo	−3.90	−4.00	4.02	0.4384	0.025	68.3%	−.3% (−14.4% to +13.8%)	0.9687	0.05
	Amantadine	−4.39	−5.00	3.69			68.0%

SD, standard deviation; CI, confidence interval; NPI, Neuropsychiatric Inventory.